Overview
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma
Description
Relmacabtagene Autoleucel treatment: Patients will receive intravenous fludarabine (25 mg/m²/day for 3 days) and cyclophosphamide (250 mg/m²/day for 3 days) for lymphodepletion, with adjustments based on hematologic and renal function.Relmacabtagene Autoleucel will be reinfused 2 to 7 days after lymphodepletion.
Sintilimab treatment: Patients will receive intravenous Sintilimab (200 mg every 3 weeks) starting on Day 28 after reinfusion, continuing until disease progression or intolerable toxicity, with a maximum duration of 1 year.
Primary endpoint: The complete response rate (CRR) at 3 months.
Eligibility
Inclusion Criteria:
- The patient must be aware of and voluntarily sign the informed consent form (ICF).
- Aged between 18 and 70 years, both male and female.
- Pathologically diagnosed with DLBCL, FL, or MCL, with histological confirmation of CD19 positivity (immunohistochemistry or flow cytometry, with flow cytometry used for re-evaluation if immunohistochemistry is CD19-negative).
- The patient must be willing to receive regorafenib and sintilimab treatment and be deemed suitable for this treatment by the investigator.
- Relapsed/refractory DLBCL, FL, or MCL.
- At least one measurable or evaluable lesion.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
- Expected survival of ≥3 months.
- Adequate function of the heart, lungs, liver, kidneys, and other organs.
Exclusion Criteria:
- History of another malignancy that has not been in complete remission for at least 2 years, except for: non-melanoma skin cancer, completely resected stage I tumors with low recurrence potential, treated localized prostate cancer, biopsy-confirmed cervical carcinoma in situ, or squamous intraepithelial lesions detected by Pap smear and so on.
- Active Hepatitis B: a) Positive for Hepatitis B surface antigen (HBsAg) and/or Hepatitis B core antibody (HBcAb) , with HBV-DNA below the lower limit of the reference value can be included.
- Hepatitis C, HIV, or syphilis infection.
- Uncontrolled systemic fungal, bacterial, viral, or other infections.
- Acute or chronic graft-versus-host disease (GVHD).
- Known hypersensitivity or allergy to any study drug or excipient.
- Clinically significant central nervous system (CNS) disease or symptoms, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychiatric illness.
- Pregnant or breastfeeding women, and women of childbearing age who do not wish to use contraception.
- Mentally ill individuals or those unable to provide informed consent.
- The investigator deems the patient unsuitable for the study due to medical, psychological, familial, social, or geographical reasons or an inability to comply with the study protocol.
- Previous CAR-T cell therapy or other gene-modified T-cell treatments.
- Previous CD19-targeted therapy.
- Previous allogeneic hematopoietic stem cell transplantation.